News | February 20, 2022
GSK pauses phase III RSV maternal vaccine candidate programme
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Resolv ER may remedy leading causes of blindness in adults
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Subscribe To Our Newsletter & Stay Updated
